Anatomic Pathology | Tissuepathology.com

Leica Biosystems Launches a 4-Plex Fluorescent Detection Kit to Advance Cancer Research

Erica Goodpaster — Thu, 05 Mar 2026 14:31:07 +0000

NEWCASTLE, United Kingdom (March 4, 2026) – Leica Biosystems, a Danaher company and a global leader in anatomic pathology solutions, streamlines multiplex immunofluorescence (IF) for oncology and translational research with the launch of its BOND 4-Plex Fluorescent Detection Kit for research use only (RUO). The new pre-assembled kit empowers researchers to achieve consistent, high-quality results while preserving […]

The post Leica Biosystems Launches a 4-Plex Fluorescent Detection Kit to Advance Cancer Research first appeared on Tissuepathology.com.

FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer

Erica Goodpaster — Wed, 18 Feb 2026 12:46:24 +0000

FDA: Device Delivers Non-invasive Therapy and Supports Care at Home White Oak, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a portable, non-invasive device that delivers alternating electrical […]

The post FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer first appeared on Tissuepathology.com.

RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment

Erica Goodpaster — Mon, 09 Feb 2026 13:33:03 +0000

Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules, announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI™), a score that is intended to […]

The post RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment first appeared on Tissuepathology.com.

Aiforia releases a new CE-IVD marked AI solution for gastric cancer diagnostics

Erica Goodpaster — Wed, 04 Feb 2026 13:09:39 +0000

February 2, 2026 at 10:00 a.m. EET. Aiforia Technologies Plc today announced the launch of a new clinical AI solution for gastric cancer diagnostics. This solution is CE-IVD marked under the IVDR. Aiforia® Gastric Cancer AI application is designed to support pathologists in the detection and reporting of gastric cancer in digitized gastric tissue samples. […]

The post Aiforia releases a new CE-IVD marked AI solution for gastric cancer diagnostics first appeared on Tissuepathology.com.

Cancer Survival Rises

Dr. Keith J. Kaplan — Wed, 14 Jan 2026 15:51:58 +0000

From CNN: The five-year cancer survival rate in the US has reached 70% for the first time, according to an American Cancer Society report released yesterday. The figure, based on diagnoses from 2015 to 2021, is up from 49% in the mid-1970s and 63% in the mid-1990s. The ACS attributes the rise to wider and earlier screening, lower smoking […]

The post Cancer Survival Rises first appeared on Tissuepathology.com.

Techcyte: Peer-Reviewed Study Demonstrates Agreement Between Techcyte’s AI-Assisted Digital Parasitology Workflow and Microscopy

Erica Goodpaster — Thu, 01 Jan 2026 15:25:48 +0000

OREM, UT, UNITED STATES, December 30, 2025 /EINPresswire.com/ — Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced the publication of a peer-reviewed study in Diagnostics (MDPI) evaluating an AI-assisted digital parasitology workflow using Techcyte’s Human Fecal Wet Mount (HFW) algorithm in a routine clinical laboratory setting. The prospective study, conducted by the […]

The post Techcyte: Peer-Reviewed Study Demonstrates Agreement Between Techcyte’s AI-Assisted Digital Parasitology Workflow and Microscopy first appeared on Tissuepathology.com.